

Epidemiology of Shiga toxin-producing *Escherichia coli* O157:H7 in Africa in review

Athumani M Lupindu*

^aDepartment of Veterinary Medicine and Public Health, College of Veterinary and Biomedical Sciences, Sokoine University of Agriculture, Morogoro, Tanzania

*Emails: amsalale@yahoo.com, alupindu@suanet.ac.tz



Shiga toxin-producing *Escherichia coli* (STEC) O157:H7 is responsible for intestinal and extra-intestinal disease syndromes in human. Isolation of the pathogen from animals, food, clinical samples and environment has been reported from all continents. A review of STEC O157:H7 in Africa from a structured literature search of the PubMed electronic database is presented. It describes the epidemiological status of the pathogen on the aspects of source, transmission, pathogenesis, disease syndromes, diagnosis, disease burden and the challenges in treatment and control strategies. About a quarter of African countries have reported isolation of STEC O157:H7 either from humans, animals, food or the environment. Different methods have been used in detection of the pathogen. Most reported human infections do not show temporal relationships with reports of isolation of the pathogen from other sources such as animals, water or food. Lack of a direct link between isolates from humans and other sources makes it difficult to point out incident specific determinants and direction of transmission. The aim of this review is to give an insight into the features of STEC O157:H7 infection in Africa and draw the attention of various stakeholders to the public health threat of the pathogen for possible interdisciplinary and multi-sectoral joint efforts in the control strategies.

Keywords: Africa, *E. coli* O157:H7, HUS, Shiga toxin, STEC

Introduction

Escherichia coli strains that cause diarrhea in humans are either enterotoxigenic *E. coli* (ETEC), enteroaggregative *E. coli* (EAEC), enteropathogenic *E. coli* (EPEC), enteroinvasive *E. coli* (EIEC), diffusely adherent *E. coli* (DAEC) or verocytotoxigenic *E. coli* (VTEC).¹ One of the VTEC strains associated with diarrhea, bloody diarrhea, haemorrhagic colitis and haemolytic uremic syndrome (HUS) is the Shiga toxin-producing *Escherichia coli* (STEC) O157:H7.² Once described as a rare serotype causing human infection,³ STEC O157:H7 is now widespread in food products^{4–6} and the environment.^{7,8} This prevalent nature and other biological characteristics, such as low infective dose,^{7,9–11} ability to express different virulence factors,⁹ long survival time in the environment¹² and the difficulty in treatment,¹³ make STEC O157:H7 an enteric pathogen of major concern worldwide. This report reviews the epidemiology of the pathogen with focus on (1) distribution, (2) disease manifestation, (3) pathogenicity, (4) isolation and characterization, (5) treatment, (6) disease burden and (7) prone groups. The aim is draw the attention of public health stakeholder to this health problem in Africa so that multi-disciplinary joint efforts can be applied in the control strategies.

Methodology

A search algorithm with terms 'shiga-toxigenic *Escherichia coli*' OR 'shiga-toxigenic' AND '*Escherichia*' AND '*coli*' OR 'shiga-toxigenic *Escherichia coli*' OR 'STEC' AND 'O157' AND 'H7' AND 'Africa' was developed in a PubMed data base on 20 June 2015 to search for articles published in last 10 years. A total of 68 journal articles were initially obtained and 37 of them were selected for the report because they described subjects of interest. A search through the reference list of the selected articles provided additional references about the pathogen in relation to hosts, reservoirs, isolation techniques, virulence, pathogenicity, clinical signs, disease burden, treatment, control and threat to the immunocompromised population. Some references of non-

African context are included in this review to cover general issues for a broader view of the pathogen.

The burden of STEC O157:H7 infection

Globally STEC causes 2 801 000 acute illnesses annually, with an incidence rate of 43.1 cases per 100 000 person-years. This burden leads to 3 890 cases of HUS and 230 deaths. Among those, a total of 10 200 cases of STEC infections occur in Africa with an incidence rate of 1.4 cases per 100 000 person-years. STEC O157:H7 contributes 10% to this burden.¹⁴

Reports of STEC O157:H7 Occurrence in Africa

Shiga toxin-producing *Escherichia coli* O157:H7 isolation has been reported from all zones of Africa (East, Central, South, North and West Africa) from humans, animals, food products and the environment. The first case of human infection was reported back in 1990 in Johannesburg, South Africa.¹⁵

In central Africa, the pathogen has been isolated in humans with haemorrhagic colitis in Bangui, Central African Republic in 1996, which led to mortalities.¹³ In 1998, STEC O157:H7 isolation from humans was reported following an outbreak of bloody diarrhoea in Cameroun.¹⁶

In east Africa, isolation of the pathogen has been reported in Tanzania, Kenya and Ethiopia. A STEC O157:H7 prevalence of more than 7% was reported in patients with diarrhoea in Morogoro, Tanzania in 2006.¹⁷ In 2012, the pathogen was isolated from cattle in the same area with a prevalence of 0.9%.¹⁸ In Kenya, STEC O157:H7 was isolated from a two-year-old boy with haemorrhagic colitis.¹⁹ Milk and cattle faeces subsequently tested positive for the pathogen in the same country.⁶ STEC O157:H7 has been isolated from beef, mutton and chevon in Ethiopia at a prevalence of 8, 2.5 and 2%, respectively,²⁰ as well as goat and sheep faeces (4.7%), skin swabs (8.7%), carcass before washing (8.1%), carcass after washing (8.7%) and water samples (4.2%).²¹

Reports on STEC O157:H7 occurrence are available from Algeria, Morocco, Tunisia and Egypt (north Africa). A study in Algeria reported a prevalence of 7% from bovine carcasses.⁵ In Morocco, a prevalence of 9.1% from dairy products and 11.1% in meat marketed in Rabat have been reported.²² STEC O157:H7 was again isolated in Morocco from raw meat products at a proportion of 9%.⁴ In 2011, a 1.9% prevalence from shellfish in Mediterranean coastline of Morocco was reported.²³ In Tunisia, 3.4% of isolates from human stool samples were shiga toxin-producing *E. coli* O157:H7.²⁴ Isolation of the pathogen from different sources has also been documented from Egypt. For instance, a survey in Egypt revealed that a prevalence of 6% from beef samples, 4% from chicken samples, 4% from lamb samples and 6% from milk samples was obtained in slaughterhouses, supermarkets and farmers' homes.²⁵

In west Africa, much of the work reported on STEC O157:H7 has been from Nigeria. In Lagos, a prevalence of 6% from patients with diarrhoea has been documented.²⁶ In the city of Ibadan, STEC O157:H7 has been isolated from the faeces of cattle, sheep, goat and pig, and also from beef, chevon (goat) and pork with a prevalence of 5%.²⁷ In Zaria, the strain has been isolated from the diarrheal stool of children under the age of 5 years with a prevalence of 5.4% and from surface water at a proportion of 2.2%.²⁸ The STEC O157:H7 isolation in Nigeria provides evidence of occurrence of the pathogen in human, animals, meat and environment (water). A study in the coastal savannah zone of Ghana did not report on the isolation of *E. coli* O157:H7 in raw milk and milk products,²⁹ but this does not guarantee absence of the pathogen. Information on recovery of *E. coli* O157:H7 from other western African countries, including Mali, Niger, Guinea, Ivory Coast, Togo, Benin, Guinea Bissau, Sierra Leone, Liberia, Mauritania, Cape Verde and Burkina Faso, were not accessed. But given the similarity between environments, there is high chance that this pathogenic *E. coli* strain exists in these countries. The lack of reports on *E. coli* O157:H7 isolation in some African countries may be due to poor diagnostic facilities, especially in rural settings where infections may pass undiagnosed.

The southern African region is comprised of Zambia, Malawi, Mozambique, Zimbabwe, Botswana, Namibia, Swaziland, Lesotho and South Africa. In South Africa, a 10.3% prevalence of STEC O157:H7 from vegetable samples in Eastern Cape province was documented.³⁰ Meat and meat products from the same location carried the pathogen at a proportion of 2.8%.³¹ Further studies reported a prevalence of 56.5% and 43.5% from stool of confirmed and non-confirmed HIV/AIDS patients, respectively, in the Eastern Cape province.³² The STEC O157:H7 isolates from meat products (7.8%), water (8.6%), vegetables (10.3%), confirmed HIV/AIDS patients (56.5%) and non-confirmed HIV/AIDS patients (43.5%) were genetically related,³⁰ and, hence, provided evidence on the possible transfer of the pathogens between different study components. In the neighbouring country of Botswana, the prevalence of STEC O157:H7 in meat cubes, minced meat and fresh sausages in Gaborone were reported to be 5.22, 3.76 and 2.26%, respectively.³³ These findings from beef-product outlets put consumers at risk of infection. Home cooked food samples (maize flour porridge, fish, vegetables and beans) investigated for pathogenic bacteria, were found to be contaminated with STEC O157:H7 at a proportion of 8% in Lungwena, Malawi.³⁴ In Mozambique, the pathogen was reported to be one of the causes of diarrhoea in children at a proportion of 1.9%.³⁵ STEC O157:H7 was reported to also cause dysentery in HIV patients in Zimbabwe at a prevalence of 8%.³⁶

Therefore, reports on isolation of pathogenic *E. coli* O157:H7 from all regions of the African continent (east, west, south, north and central) show that the pathogen is found throughout Africa. A total of 15 countries have reported recovery of pathogenic *E. coli* O157:H7 either from humans, animals, food products or the environment. Out of 30 reviewed cases, 10 (33.3%) come from human patients and the remaining 20 isolations (66.7%) belong to food stuffs,⁸ cattle,⁵ water³ and others (2 sheep and goats, 1 vegetable and 1 shell fish) (Table 1).

Transmission of STEC O157:H7

STEC O157:H7 is an enteric pathogen that is transmitted to humans through ingestion of contaminated food, or hands to mouth.^{7,37} Person-to-person contact can lead to transmission of the pathogen through the oral-faecal route.⁹ The infectious dose that has caused disease symptoms in humans has been reported to be as low as 4 to 24 organisms.^{7,11} Ruminants are said to be reservoirs, whereby cattle are regarded as principal sources of infections.^{6,38–42} However other ruminant species, such as goats, sheep,^{21,27} and buffaloes,⁴³ serve as a source of the pathogen, with the exception for camels.⁴⁴ Non-ruminant animals such as pigs^{27,38,39} and pigeons⁴⁵ are also reported to carry this strain of pathogenic *E. coli*. Fish in contaminated water have been reported to harbour STEC O157:H7.⁴⁶ A single dose of 100 CFU is sufficient to infect cattle,⁴⁷ while sheep have been infected by a single oral dose of 10⁵ CFU.⁴⁸ These doses can be acquired by ingestion of as little as 0.1 g of manure containing 10⁶ CFU/g.⁴⁸ Shedding of the pathogen in cattle is intermittent,^{45,49} the duration of shedding by cattle is less than a month and shedding peaks occur during the months of summer.^{49,50} Weaning calves are reported to shed more bacteria than other age groups.^{50,51} These findings suggest that having negative results at a particular point in time does not indicate absence of STEC O157:H7. Moreover, the reported prevalence of STEC O157:H7 may be lower or higher than the real situation depending on the composition of cattle, by age, in the study.

Accidental ingestion of STEC O157:H7 following contact with infected animals or the contaminated environment has led to human infection.^{7,52,53} Contaminated food products such as beef,^{4,5,20,22,25,33} chevon, mutton,^{20,21,25} milk and chicken may lead to human infection.^{22,25} Marine environmental contamination has also posed a risk because of isolation of the pathogen from shellfish.²³ Convenient foods under poor preparation or handling have also been reported to play a role in propagation of this pathogen.³⁷ Moreover, inanimate objects such as soil,⁷ water,^{28,46} marine sediments²³ and manure⁵⁰ are a source of the pathogen. The risk is potentiated by the ability of the pathogen to survive harsh conditions, such as the low pH of dairy products,^{54,55} or in manure for more than four months.⁴⁸ Generally, the risk factors for STEC O157:H7 infections include contact with animals and their environment and poor personal hygiene, such as not washing hands after handling animals or prior to eating.^{7,52,53} These findings and reports call for hygiene observance after contact with animals, the suspected environment or during preparation of foods.

In Africa, evidence of STEC O157:H7 transmission between humans, animals and environment is not clear. From the reports in this review, isolation of STEC O157:H7 from humans was driven by the occurrence of disease syndromes, such as diarrhoea, while detection of the pathogen from animals, animal product and the environment was part of routine research work. There is no

temporal relationship in isolation from these two ends. Under such a scenario, it is difficult to establish events and direction of transmission, as well as to quantify the risk of pathogen transfer between humans, livestock and the environment. There is a need to investigate the possible sources and to quantify risk factors every time STEC O157:H7 is isolated from humans to ensure that prevention and control strategies are appropriate.

Isolation and characterisation of STEC O157:H7

Like any other member of the family Enterobacteriaceae, Shiga toxin-producing *Escherichia coli* O157:H7 can be isolated on MacConkey agar, followed by conventional biochemical or serological tests to confirm that the isolates are *E. coli*. Isolation can also be done by use of sorbitol MacConkey agar whereby most STEC O157:H7 are distinguished from other strains by their inability to ferment sorbitol. Direct inoculation of a sample on sorbitol MacConkey agar has been employed, but has been proven to be less sensitive compared to immunomagnetic separation.^{56,57} Some studies have employed both sorbitol MacConkey agar and immunomagnetic separation to maximise the chances of isolating the pathogen.³² STEC O157:H7 strains should be distinguished from Non-O157:H7 strains, which also do not ferment sorbitol.¹⁸ Either of these *E. coli* isolation options can be accomplished by performing an agglutination test using antibodies against a somatic antigen for O157:H7 and a flagella antigen for H7. Polymerase chain reaction (PCR) for the detection of shiga toxin-producing genes in *E. coli* O157:H7 remains a gold standard detection method.⁵⁷ Detection of the bacteria or toxins may take more than 24 h.⁵⁸ In some instances, DNA hybridisation

has been performed to affirm additional virulence genes and phenotypic activities of shiga toxin-producing genes proven by Vero-cell cytotoxicity assay.

In the present review, sorbitol MacConkey agar was used in isolation of STEC O157:H7 in 21 out of 24 reports from Africa. An immunomagnetic separation technique was employed in seven reports, in which it was used together with sorbitol MacConkey agar. After isolation, the characterisation of *E. coli* O157:H7 was done by polymerase chain reaction (PCR) to detect the shiga toxin-producing genes (14 reports), O157 antisera for detection of somatic antigen O157 (18 reports) and dot plot DNA hybridisation was used to confirm PCR results (2 reports). Serotyping of O157:H7 antigens was performed in four studies, while Vero-cell cytotoxicity assays were performed to test for cytopathic effects on Vero-cell monolayers in six studies that are included in this review (Table 1). The use of molecular methods (PCR) to detect shiga toxin-producing genes in only 14 out of 24 (58%) studies in this review could have resulted in missed detection and under-reporting of STEC in Africa. All these STEC O157:H7 detection methods required more than 24 h to complete. Moreover, not many laboratories in Africa can afford these diagnostic procedures. There is a need to improve diagnostic facilities in Africa – even by starting with a few reference laboratories in each African country – which will enable quick and accurate detection of STEC O157:H7 infection. This will help to avoid inappropriate management of cases, such as use of antimicrobials which are easily accessed in Africa and often without prescription, for any enteric illness including STEC O157:H7 infection.

Table 1: Sources and methods of STEC O157 isolation and characterisation in African continent

Country	Source	Isolation and characterisation method*	Author
Central African Republic	Human	PCR	Germani <i>et al.</i> 1997
	Cattle, fish, water, environment	SMAC, anti O157 antisera and VCA	Tuyet <i>et al.</i> 2006
Cameroon	Human	SMAC, anti O157 antisera, O:H serotyping and VCA	Cunin <i>et al.</i> 1999
Tanzania	Human	SMAC, IMS, anti O157 antisera and PCR	Raji <i>et al.</i> 2008
	Cattle	SMAC, anti O157 antisera, PCR, DNA hybridization, O:H serotyping and VCA	Lupindu <i>et al.</i> 2014
Kenya	Human	PCR, DNA hybridization, VCA	Sang <i>et al.</i> 1996
	Cattle, food (milk)	SMAC, anti O157 antisera and PCR	Kang'ethe <i>et al.</i> 2007
Ethiopia	Beef, mutton and chevon	SMAC, O:H serotyping	Hiko <i>et al.</i> 2008
	Water, sheep, goats	IMS, SMAC, anti O157 antisera and PCR	Mersha <i>et al.</i> 2010
Algeria	Cattle (carcass)	SMAC, anti O157:H7 antisera, PCR, DNA hybridization	Chahel <i>et al.</i> 2006
Morocco	Food (Dairy and meat products)	IMS, SMAC, anti O157 antisera and PCR	Benkerroum <i>et al.</i> 2004
	Raw meat products	IMS, SMAC, anti O157 antisera and PCR	Beneduce <i>et al.</i> 2008
	Shellfish	SMAC, anti O157 antisera and PCR	Bennani <i>et al.</i> 2011
Tunisia	Human	SMAC, anti O157 antisera, PCR and VCA	Al-Gallas <i>et al.</i> 2006
Egypt	Beef, chicken, lamb and milk	SMAC and O:H serotyping	Abdul-Raouf <i>et al.</i> 1995
Nigeria	Human	SMAC, anti O157 antisera. VCA	Olorunshola <i>et al.</i> 2000
	Cattle, food, sheep, goat, pig	SMAC and anti O157 antisera	Ojo <i>et al.</i> 2010
	Human, water	SMAC, anti O157 antisera	Chigor <i>et al.</i> 2010
South Africa	Human, vegetable	IMS, SMAC and PCR	Abong'o <i>et al.</i> 2008
	Food	IMS, SMAC and PCR	Abong'o and Momba 2009
Botswana	Food (meat)	IMS, SMAC and anti O157 antisera	Magwira <i>et al.</i> 2004
Malawi	Maize porridge, vegetable, beans	SMAC, anti O157 antisera	Taulo <i>et al.</i> 2008
Mozambique	Human	PCR	Mandomando <i>et al.</i> 2007
Zimbabwe	Human	SMAC	Gwavava <i>et al.</i> 2001

*SMAC = sorbitol MacConkey agar, IMS = immunomagnetic separation, VCA = Vero-cell assay.

Pathogenicity of STEC O157:H7 infection

STEC O157:H7 possesses different virulence factors that are important in pathogenicity. The major virulence factor is the shiga toxin. Two forms of the toxin, stx1 and stx2 encoded by *stx1* and *stx2* genes are known⁵⁹ and reported to be responsible for haemorrhagic uremic syndrome (HUS).⁶⁰ The *stx1* is divided into three subtypes (*stx1a*, *stx1c* and *stx1d*) while seven subtypes form the *stx2* group (*stx2a*, *stx2b*, *stx2c*, *stx2d*, *stx2e*, *stx2f* and *stx2g*).⁶¹ Of the two groups, subtypes of *stx2* are associated with more severe HUS syndrome.⁶² Shiga toxins, which are protein molecules, bind to eukaryotic surface cells and inhibit protein synthesis with the death of host cells as a consequence.⁶³ Intimin is another virulence factor which is coded by attaching and effacing the *eae* gene.⁶⁴ Intimin is reported to facilitate attachment of bacteria to intestinal epithelia during colonisation resulting into production of lesions and diarrhoea.^{59,65,66} This virulence factor is also possessed by enteropathogenic *E. coli* (EPEC).⁶⁷ Enterohaemolysin is another virulence factor for STEC O157:H7. This protein toxin damages cell membranes of erythrocytes and is used as a surrogate tool in detection of shiga toxin-producing *E. coli*.^{68–70} Although enterohaemolysin activity can easily be visualised on blood agar cultures, confirmation is usually achieved by PCR amplification of the *ehxA* gene.^{59,68} Some other *E. coli* strains such as O26, O103, O111, O118, O128, O121, O45 and O145 can produce disease syndromes and have been reported to be enterohaemolysin-positive and produce shiga toxins.^{68,70–72} The synergic effects of these virulence factors make STEC O157:H7 a potential pathogen to humans. All virulence genes, namely *stx1*, *stx2*, *eae* and *ehxA* genes, have been detected in humans, livestock, food products and the environment in eight different combinations as reported in 22 studies from Africa.⁸ The most dominant combination was *stx1*+*stx2*. Cattle are the most common source of STEC O157:H7, as shown in Table 2. Therefore, it is important to consider the use of diagnostic approaches which target different genes so as to increase the sensitivity of STEC O157:H7-related studies.

Disease syndromes caused by STEC O157:H7

To date, STEC O157:H7 has been reported to cause intestinal and extra-intestinal disease symptoms in humans. Disease symptoms may take different forms such as diarrhoea,¹⁷ haemorrhagic colitis^{13,19} or haemolytic uremic syndrome.¹³ Haemolytic uremic syndrome, which is characterised by thrombocytopenia,

haemolytic anaemia and nephropathy, may come as a complication of STEC O157:H7 infection following prolonged illness or sometimes disease management such as the use of antibiotics.⁷³ However, some humans do not show signs of disease despite infection and these are known as asymptomatic carriers.^{24,74} Disease syndromes by STEC O157:H7 in Africa have been reported to take the form of an epidemic^{13,16} whereby the 1992 outbreak in Swaziland and South Africa are reported to be the largest in Africa.⁷⁵ However, sporadic forms of the disease have posed a threat to public health as well.¹⁹

Treatment of STEC O157:H7 infection

Infections with shiga toxins-producing bacteria such as *Shigella dysenteriae* type I and STEC are controlled by the use of antibiotics and supportive therapies.^{13,76} However, in complicated forms of infection, like with HUS, antibiotics are not effective.^{13,76} Administration of antibiotics to patients infected with STEC O157:H7 is reported to increase the release of shiga toxins and thus increasing the risk of developing HUS.^{13,73} This is thought to be due to the increased release of toxins following death of STEC.⁷³ The case is different, however, in *S. dysenteriae* type I infection where early antimicrobial therapy lowers the risk of developing HUS.⁷⁶ Therefore, it is important to establish the etiology of an enteric disease before administration of antibiotics because it may worsen the prognosis in case of a STEC infection. This demand presents a challenge in developing countries where diagnostics do not match the requirements and antibiotics are haphazardly used.^{77,78}

Antimicrobial resistance in STEC O157:H7

Different studies in Africa have reported resistance of STEC O157:H7 to different antimicrobials. For instance, occurrence of multi-drug resistant STEC O157:H7 isolated from humans, animals and the environment has been reported in Egypt,⁷⁹ while isolation of multi-drug resistant STEC O157:H7 from cattle in South Africa have also been reported.⁸⁰ Similar results have been reported by Chigor *et al.* in Nigeria. Multi-drug resistance may seem of less importance since antimicrobials are not used to treat STEC O157:H7 infection, but there may be a contribution towards selection for resistance genes.

Control of STEC O157:H7 infection

Research on vaccination of reservoirs in an effort to reduce bacteria shedding has shown signs of success,⁸¹ but the practicality of this approach is questionable due to the use of transgenic tobacco plant cells.⁹ Some substances such as essential oils from *Cinnamomum zeylanicum* have shown bactericidal activities.⁸² But, the above efforts plus dietary manipulations are not promising strategies. Thus, hygienic management of animal and food products remain better options in control of STEC transmission. Moreover, we suggest structuring of an inter-sectoral cooperation between the veterinary (where the main reservoir, cattle, belong) and medical profession (where patients are cared for). A platform for exchange of information and strategies can help in controlling the emergence and spread of the pathogen.

STEC O157:H7 special prone group

Shiga toxin-producing *E. coli* infect all sexes and ages, but many reported cases involve young and elderly people.^{19,35} However, the susceptibility spectrum is broadening such that, apart from the usual prone groups of the young and elderly, immunocompromised people form part of a group at risk. Cases of STEC O157:H7 infections in people living with HIV/AIDS have been reported in Africa.^{32,36} This poses a big challenge because

Table 2: STEC O157:H7 virulence factor combinations from studies in Africa

Gene combination	Source	Reports	Countries
<i>stx1</i>	Cattle feces, milk	2	Kenya
<i>stx2</i>	Cattle feces, human stool	2	CAR* and Kenya
<i>stx1</i> + <i>eae</i>	Human stool	1	CAR*
<i>stx1</i> + <i>stx2</i>	Cattle feces, water, fish, human stool, milk, beef, goat, sediment	6	CAR, Ethiopia, Egypt and Morocco
<i>eae</i> + <i>ehxA</i>	Cattle feces, pig	1	South Africa
<i>eae</i> + <i>stx2</i> + <i>ehxA</i>	Cattle feces, cattle carcass	2	Tanzania and Algeria
<i>stx1</i> + <i>stx2</i> + <i>eae</i>	Human stool, beef	2	Cameroon and Morocco
<i>stx1</i> + <i>stx2</i> + <i>eae</i> + <i>ehxA</i>	Cattle feces, goat, sheep, pig, human stool	2	Nigeria, South Africa and Tunisia

*Central African Republic.

Africa has a large share in the global HIV/AIDS burden. Furthermore, complications of STEC O157:H7 infections, e.g. HUS, are aggravated by the use of antibiotics in HIV/AIDS patients and are essential to combat other opportunistic microorganism infections. Subsequently, there becomes imbalance between the desire to alleviate the effects of opportunistic pathogens and shiga-toxins in HIV/AIDS patients due to contrasting outcomes of antimicrobial use. Reports of antibiotic use, such as ciprofloxacin, meropenem, fosfomycin, chloramphenicol, azithromycin and rifaximin, in treatment of STEC O104:H4 infections without induction of shiga toxin release^{83,84} are promising. More research on these antibiotics is required to ascertain the possibility of their use to treat STEC O157:H7 patients with HIV/AIDS.

STEC non-O157:H7

Although STEC O157:H7 is the most commonly reported cause of human gastroenteritis, STEC non-O157:H7 pose an increasing risk in public health. When isolation procedures do not specifically target O157:H7 strain, the proportion of STEC isolation skews towards non-O157:H7. In Africa most of the major worldwide-recognised non-O157 serotypes (O103, O111, O145 and O26) have been isolated from different parts of the continent. For instance, in Egypt STEC O26, O114, O125 and O158 have been isolated from humans, cattle, sheep, chickens and water.^{85,86} In Tanzania, STEC O113 has been isolated from cattle faeces.¹⁸ In South Africa, screening of STEC isolates from diarrhoeic human patients revealed isolation of STEC O4, O5, O21, O26, O84 and O111, in addition to O157.⁷² In the same country, STEC O26 and O145 have been isolated from pig faeces.⁸⁷ These reports suggest that whenever STEC-related gastroenteritis is suspected, we should also consider other strains of STEC, not only O157, because failure to isolate O157:H7 may mislead the cause of illness. On the other hand, diagnosis of STEC-related gastroenteritis based on detection of shiga toxins could help in avoiding this discrimination.

The most recent and striking non-STEC O157-related HUS outbreak in Germany in 2011 was caused by O104:H4 strain. This strain had previously been isolated from diarrhoeic patients in Central African Republic in the mid-nineties.⁸⁸

Conclusion

Isolation of STEC O157:H7 from animals and food products reported from almost all over Africa suggests a high risk for human infection. Lack of proper laboratory facilities, especially in rural settings of Africa, interferes with definitive diagnoses and, hence, patients are treated tentatively. As such, antibiotic prescribed to patients with gastroenteritis can be fatal especially in case of STEC O157:H7 infection. Additionally, difficulty in managing infection cases and time consuming diagnostic procedures call for preventive approaches rather than curative measures. Proper cattle and manure handling practices as well as public awareness on the epidemiology of the pathogen should be instituted. Vehicles of transmission, such as food products and water, should be decontaminated so as to prevent health implications due to STEC O157:H7 infection.

Conflict of interest – The author declares no conflict of interest.

Acknowledgement – This review was done during execution of the project 'Opportunities and challenges in peri-urban livestock farming in Tanzania' (P6-08-Tan). The author wishes to thank the Ministry of Foreign Affairs of Denmark and the Danish International Development Agency (DANIDA) for financial support to the project.

References

- Nataro JP, Kaper JB. Diarrheagenic *Escherichia coli*. Clin Microbiol Rev. 1998;11(1): 142–201.
- Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare *Escherichia coli* serotype. N Eng J Med. 1983;308(12): 681. <https://doi.org/10.1056/NEJM198303243081203>
- Wells JG, Davis BR, Wachsmuth IK, et al. Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare *Escherichia coli* serotype. J Clin Microbiol. 1983;18(3): 512–20.
- Beneduce L, Spano G, Nabi AQ, et al. Occurrence and characterization of *Escherichia coli* O157 and other serotypes in raw meat products in Morocco. J Food Protect. 2008;71(10): 2082–6. <https://doi.org/10.4315/0362-028X-71.10.2082>
- Chahed A, China B, Mainil J, et al. Prevalence of enterohaemorrhagic *Escherichia coli* from serotype O157 and other attaching and effacing *Escherichia coli* on bovine carcasses in Algeria. J Appl Microbiol. 2006 Aug;101(2): 361–8. <https://doi.org/10.1111/jam.2006.101.issue-2>
- Kang'ethe EK, Onono JO, McDermott B, et al. Isolation of *E. coli* O157:H7 from milk and cattle faeces from urban dairy farming and non dairy farming neighbour households in Dagoretti Division, Nairobi, Kenya: prevalence and risk factors. East Afr Med J 2007 Nov;84(11 Suppl): S65–75.
- Howie H, Mukerjee A, Cowden J, et al. Investigation of an outbreak of *Escherichia coli* O157 infection caused by environmental exposure at a scout camp. Epidemiol Infect. 2003;131(3): 1063–9. <https://doi.org/10.1017/S0950268803001250>
- Müller EE, Ehlers MM, Grabow WOK. The occurrence of *E. coli* O157: H7 in South African water sources intended for direct and indirect human consumption. Water Res. 2001;35(13): 3085–8. [https://doi.org/10.1016/S0043-1354\(00\)00597-2](https://doi.org/10.1016/S0043-1354(00)00597-2)
- Caprioli A, Morabito S, Brugère H, et al. Enterohaemorrhagic *Escherichia coli*: emerging issues on virulence and modes of transmission. Veterinary research. 2005;36(3): 289–311. <https://doi.org/10.1051/vetres:2005002>
- Hancock DD, Besser TE, Kinsel ML, et al. The prevalence of *Escherichia coli* O157:H7 in dairy and beef cattle in Washington State. Epidemiol Infect. 1994 Oct;113(2): 199–207. <https://doi.org/10.1017/S0950268800051633>
- Strachan NJC, Fenlon DR, Ogden ID. Modelling the vector pathway and infection of humans in an environmental outbreak of *Escherichia coli* O157. FEMS Microbiol Lett. 2001;203(1): 69–73. <https://doi.org/10.1111/fml.2001.203.issue-1>
- Avery LM, Killham K, Jones DL. Survival of *E. coli* O157:H7 in organic wastes destined for land application. J Appl Microbiol. 2005;98(4): 814–22. <https://doi.org/10.1111/jam.2005.98.issue-4>
- Germani Y, Soro B, Vohito M, et al. Enterohaemorrhagic *Escherichia coli* in Central African Republic. The Lancet. 1997;349: 1670. [https://doi.org/10.1016/S0140-6736\(05\)62636-0](https://doi.org/10.1016/S0140-6736(05)62636-0)
- Majowicz SE, Scallan E, Jones-Bitton A, et al. Global incidence of human Shiga toxin-producing *Escherichia coli* infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis. 2014;11(6): 447–55. <https://doi.org/10.1089/fpd.2013.1704>
- Browning NG, Botha JR, Sacho H, et al. *Escherichia coli* O157: H7 haemorrhagic colitis. Report of the first South African case. South African J Surg Suid-Afrikaanse tydskrif vir chirurgie. 1990;28(1): 28.
- Cunin P, Tedjouka E, Germani Y, et al. An epidemic of bloody diarrhea: *Escherichia coli* O157 emerging in Cameroon? Emerg Infect Dis. 1999 Mar-Apr;5(2):285–90. <https://doi.org/10.3201/eid0502.990217>
- Raji MA, Minga UM, Machang'u RS. Prevalence and characterization of verocytotoxin producing *Escherichia coli* O157 from diarrhoea patients in Morogoro, Tanzania. Tanzan J Health Res. 2008 Jul;10(3): 151–8.
- Lupindu AM, Olsen JE, Ngowi HA, et al. Occurrence and characterization of Shiga Toxin-producing *Escherichia coli* O157:H7 and other non-sorbitol-fermenting *E. coli* in cattle and humans in urban areas of Morogoro, Tanzania. Vector-Borne Zoonotic Dis. 2014;14(7): 503–10. <https://doi.org/10.1089/vbz.2013.1502>
- Sang WK, Saidi SM, Yamamoto H, et al. Haemorrhagic colitis due to *Escherichia coli* O157:H7 in Kenya. J Trop Pediatr. 1996 Apr;42(2): 118–9. <https://doi.org/10.1093/tropej/42.2.118>
- Hiko A, Asrat D, Zewde G. Occurrence of *Escherichia coli* O157:H7 in retail raw meat products in Ethiopia. J Infect Dev Ctries. 2008;2(5): 389–93.

21. Mersha G, Asrat D, Zewde BM, et al. Occurrence of *Escherichia coli* O157:H7 in faeces, skin and carcasses from sheep and goats in Ethiopia. *Lett Appl Microbiol.* 2010 Jan;50(1):71–6. <https://doi.org/10.1111/lam.2009.50.issue-1>
22. Benkerroum N, Bouhlal Y, El Attar A, et al. Occurrence of shiga toxin-producing *Escherichia coli* O157 in selected dairy and meat products marketed in the city of Rabat, Morocco. *J Food Protect.* 2004;67(6):1234–7. <https://doi.org/10.4315/0362-028X-67.6.1234>
23. Bennani M, Badri S, Baibai T, et al. First detection of Shiga toxin-producing *Escherichia coli* in shellfish and coastal environments of Morocco. *Appl Biochem Biotechnol.* 2011 Sep;165(1):290–9. <https://doi.org/10.1007/s12010-011-9251-x>
24. Al-Gallas N, Bahri O, Aissa RB. Prevalence of shiga toxin-producing *Escherichia coli* in a diarrheagenic Tunisian population, and the report of isolating STEC O157: H7 in Tunis. *Curr Microbiol.* 2006;53(6): 483–90. <https://doi.org/10.1007/s00284-006-0184-5>
25. Abdul-Raouf UM, Ammar MS, Beuchat LR. Isolation of *Escherichia coli* O157:H7 from some Egyptian foods. *Int J Food Microbiol.* 1996 Apr;29(2–3):423–6. [https://doi.org/10.1016/0168-1605\(95\)00076-3](https://doi.org/10.1016/0168-1605(95)00076-3)
26. Olorunshola ID, Smith SI, Coker AO. Prevalence of EHEC O157: H7 in patients with diarrhoea in Lagos, Nigeria. *Apmis.* 2000;108(11): 761–3. <https://doi.org/10.1034/j.1600-0463.2000.d01-26.x>
27. Ojo OE, Ajuwape ATP, Otesile EB, et al. Potentially zoonotic shiga toxin-producing *Escherichia coli* serogroups in the faeces and meat of food-producing animals in Ibadan, Nigeria. *Int J Food Microbiol.* 2010;142(1–2):214–21. <https://doi.org/10.1016/j.jfoodmicro.2010.06.030>
28. Chigor VN, Umoh VJ, Smith SI, et al. Multidrug resistance and plasmid patterns of *Escherichia coli* O157 and other *E. coli* isolated from diarrhoeal stools and surface waters from some selected sources in Zaria, Nigeria. *Int J Environ Res Public Health.* 2010;7(10):3831–41. <https://doi.org/10.3390/ijerph7103831>
29. Addo KK, Mensah GI, Aning KG, et al. Microbiological quality and antibiotic residues in informally marketed raw cow milk within the coastal savannah zone of Ghana. *Trop Med Int Health.* 2011 Feb;16(2): 227–32. <https://doi.org/10.1111/tmi.2011.16.issue-2>
30. Abong'o BO, Momba MNB. Prevalence and potential link between *E. coli* O157: H7 isolated from drinking water, meat and vegetables and stools of diarrhoeic confirmed and non-confirmed HIV/AIDS patients in the Amathole District - South Africa. *J Appl Microbiol.* 2008;105(2): 424–31. <https://doi.org/10.1111/jam.2008.105.issue-2>
31. Abong'o BO, Momba MNB. Prevalence and characterization of *Escherichia coli* O157: H7 isolates from meat and meat products sold in Amathole District, Eastern Cape Province of South Africa. *Food Microbiol.* 2009;26(2):173–6. <https://doi.org/10.1016/j.fm.2008.10.001>
32. Abong'o BO, Momba MNB, Mwambakane JN, et al. Prevalence of *Escherichia coli* O157:H7 among diarrhoeic HIV/AIDS patients in Eastern Cape Province-South Africa. *Pakistan J Biological Sci.* 2008;11(8): 1066–75.
33. Magwira CA, Gashe BA, Collison EK. Prevalence and antibiotic resistance profiles of *Escherichia coli* O157:H7 in beef products from retail outlets in Gaborone, Botswana. *J Food Prot.* 2005 Feb;68(2): 403–6. <https://doi.org/10.4315/0362-028X-68.2.403>
34. Taulo S, Wetlesen A, Abrahamsen R, et al. Microbiological hazard identification and exposure assessment of food prepared and served in rural households of Lungwena, Malawi. *Int J Food Microbiol.* 2008 Jul 15;125(2): 111–6. <https://doi.org/10.1016/j.jfoodmicro.2008.02.025>
35. Mandomando IM, Macete EV, Ruiz J, et al. Etiology of diarrhea in children younger than 5 years of age admitted in a rural hospital of southern Mozambique. *Am J Trop Med Hyg.* 2007;76(3):522–7.
36. Gwavava C, Chihota VN, Gangaidzo IT, et al. Dysentery in patients infected with human immunodeficiency virus in Zimbabwe: an emerging role for *Schistosoma mansoni* and *Escherichia coli* O157? *Ann Trop Med Parasitol.* 2001;95(5):509–13. <https://doi.org/10.1080/00034983.2001.11813663>
37. Tuttle J, Gomez T, Doyle MP, et al. Lessons from a large outbreak of *Escherichia coli* O157: H7 infections: insights into the infectious dose and method of widespread contamination of hamburger patties. *Epidemiol Infect.* 1999;122(2):185–92. <https://doi.org/10.1017/S0950268898001976>
38. Ateba CN, Bezuidenhout CC. Characterisation of *Escherichia coli* O157 strains from humans, cattle and pigs in the North-West Province, South Africa. *Int J Food Microbiol.* 2008;128(2):181–8. <https://doi.org/10.1016/j.jfoodmicro.2008.08.011>
39. Ateba CN, Mbewe M. Detection of *Escherichia coli* O157: H7 virulence genes in isolates from beef, pork, water, human and animal species in the northwest province, South Africa: public health implications. *Res Microbiol.* 2011;162(3):240–8. <https://doi.org/10.1016/j.resmic.2010.11.008>
40. Cobbaut K, Houf K, Buvens G, et al. Occurrence of non-sorbitol fermenting, verocytotoxin-lacking *Escherichia coli* O157 on cattle farms. *Vet Microbiol.* 2009 Jul 2;138(1–2):174–8. <https://doi.org/10.1016/j.vetmic.2009.02.008>
41. Heuvelink AE, Valkenburgh SM, Tilburg J, et al. Public farms: hygiene and zoonotic agents. *Epidemiol Infect.* 2007;135(7):1174–83.
42. Kaddu-Mulindwa DH, Aisu T, Gleier K, et al. Occurrence of Shiga toxin-producing *Escherichia coli* in fecal samples from children with diarrhea and from healthy zebu cattle in Uganda. *Int J Food Microbiol.* 2001;66(1):95–101. [https://doi.org/10.1016/S0168-1605\(00\)00493-1](https://doi.org/10.1016/S0168-1605(00)00493-1)
43. Dorn CR, Angrick EJ. Serotype O157:H7 *Escherichia coli* from bovine and meat sources. *J Clin Microbiol.* 1991 Jun;29(6):1225–31.
44. El-Sayed A, Ahmed S, Awad W. Docamels (*Camelus dromedarius*) play an epidemiological role in the spread of Shiga Toxin producing *Escherichia coli* (STEC) infection? *Trop Anim Health Prod.* 2008;40(6):469–73. <https://doi.org/10.1007/s11250-007-9122-1>
45. Shere JA, Bartlett KJ, Kaspar CW. Longitudinal study of *Escherichia coli* O157: H7 dissemination on four dairy farms in Wisconsin. *Appl Environ Microbiol.* 1998;64(4):1390–9.
46. Tuyet DT, Yassibanda S, Nguyen Thi PL, et al. Enteropathogenic *Escherichia coli* O157 in Bangui and N'Goila, Central African Republic: a brief report. *Am J Trop Med Hyg.* 2006 Sep;75(3):513–5.
47. Hancock DD, Besser TE, Rice DH, editors. Ecology of *Escherichia coli* O157: H7 in cattle and impact of management practices. In: Kaper JB, O'Brien A D, editors, *Escherichia coli* O157:H7 and other Shiga toxin-producing *E. coli* strains. Washington, DC: ASM Press; 1997. pp. 85–91.
48. Kudva IT, Blanch K, Hovde CJ. Analysis of *Escherichia coli* O157:H7 survival in ovine or bovine manure and manure slurry. *Appl Environ Microbiol.* 1998 Sep;64(9):3166–74.
49. Besser TE, Hancock DD, Pritchett LC, et al. Duration of detection of fecal excretion of *Escherichia coli* O157:H7 in cattle. *J Infect Dis.* 1997;175: 726–9. <https://doi.org/10.1093/infdis/175.3.726>
50. Hutchison ML, Walters LD, Avery SM, et al. Analyses of livestock production, waste storage, and pathogen levels and prevalences in farm manures. *Appl Environ Microbiol.* 2005;71(3):1231–6. <https://doi.org/10.1128/AEM.71.3.1231-1236.2005>
51. Laegreid WW, Elder RO, Keen JE. Prevalence of *Escherichia coli* O157: H7 in range beef calves at weaning. *Epidemiol Infect.* 1999;123(2):291–8. <https://doi.org/10.1017/S0950268899002757>
52. Crump JA, Sulka AC, Langer AJ, et al. An outbreak of *Escherichia coli* O157: H7 infections among visitors to a dairy farm. *N Eng J Med.* 2002;347(8):555–60. <https://doi.org/10.1056/NEJMoa020524>
53. Smith KE, Stenzel SA, Bender JB, et al. Outbreaks of enteric infections caused by multiple pathogens associated with calves at a farm day camp. *Pediatr Infect Dis J.* 2004;23(12):1098–104.
54. Dlamini BC, Buys EM. Adaptation of *Escherichia coli* O157: H7 to acid in traditional and commercial goat milk amasi. *Food Microbiol.* 2009;26(1):58–64. <https://doi.org/10.1016/j.fm.2008.07.007>
55. Tsegaye M, Ashenafi M. Fate of *Escherichia coli* O157:H7 during the processing and storage of Ergo and Ayib, traditional Ethiopian dairy products. *Int J Food Microbiol.* 2005 Aug 15;103(1):11–21. <https://doi.org/10.1016/j.jfoodmicro.2004.12.006>
56. Chapman PA, Siddons CA. A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing *Escherichia coli* O157 from cases of bloody diarrhoea, non-bloody diarrhoea and asymptomatic contacts. *J Med Microbiol.* 1996;44(4):267–71. <https://doi.org/10.1099/00222615-44-4-267>
57. Cubbon MD, Coia JE, Hanson MF, et al. A comparison of immunomagnetic separation, direct culture and polymerase chain reaction for the detection of verocytotoxin-producing *Escherichia coli* O157 in human faeces. *J Med Microbiol.* 1996;44(3):219–22. <https://doi.org/10.1099/00222615-44-3-219>

58. Gould LH. Update: recommendations for diagnosis of shiga toxin-producing *Escherichia coli* infections by clinical laboratories. Clin Microbiol Newslett. 2012;34(10):75–83. <https://doi.org/10.1016/j.clinmicnews.2012.04.004>
59. Gallien P. Detection and subtyping of Shiga toxin-producing *Escherichia coli* (STEC). Methods Mol Biol. 2003;216: 163–84.
60. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing *Escherichia coli* infections. Clin Microbiol Rev. 1998;11(3): 450–79.
61. Scheutz F, Teel LD, Beutin L, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol. 2012;50(9): 2951–63. <https://doi.org/10.1128/JCM.00860-12>
62. Persson S, Olsen KE, Ethelberg S, et al. Subtyping method for *Escherichia coli* Shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. J Clin Microbiol. 2007;45(6): 2020–4. <https://doi.org/10.1128/JCM.02591-06>
63. Sandvig K. Shiga toxins. Toxicon. 2001;39(11):1629–35. [https://doi.org/10.1016/S0041-0101\(01\)00150-7](https://doi.org/10.1016/S0041-0101(01)00150-7)
64. Jerse AE, Yu J, Tall BD, et al. A genetic locus of enteropathogenic *Escherichia coli* necessary for the production of attaching and effacing lesions on tissue culture cells. Proc Natl Acad Sci U S A. 1990 Oct;87(20): 7839–43. <https://doi.org/10.1073/pnas.87.20.7839>
65. McDaniel TK, Jarvis KG, Donnenberg MS, et al. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1664–8. <https://doi.org/10.1073/pnas.92.5.1664>
66. Moon HW, Whipp SC, Argenzio RA, et al. Attaching and effacing activities of rabbit and human enteropathogenic *Escherichia coli* in pig and rabbit intestines. Infect Immun. 1983 Sep;41(3): 1340–51.
67. China B, Goffaux F, Pirson V, et al. Comparison of eae, tir, espA and espB genes of bovine and human attaching and effacing *Escherichia coli* by multiplex polymerase chain reaction. FEMS Microbiol Lett. 1999 Sep 1;178(1):177–82. <https://doi.org/10.1111/fml.1999.178.issue-1>
68. El Sayed Zaki M, El-Adrosy H. Diagnosis of Shiga toxin producing *Escherichia coli* infection, contribution of genetic amplification technique. Microbes Infect. 2007 Feb;9(2):200–3. <https://doi.org/10.1016/j.micinf.2006.11.005>
69. Jürgens D, Özel M, Takaisi-Kikuni NB. Production and characterization of *Escherichia coli* enterohemolysin and its effects on the structure of erythrocyte membranes. Cell Biol Int. 2002;26(2):175–86. <https://doi.org/10.1006/cbir.2001.0831>
70. Schmidt H, Beutin L, Karch H. Molecular analysis of the plasmid-encoded hemolysin of *Escherichia coli* O157: H7 strain EDL 933. Infect Immun. 1995;63(3): 1055–61.
71. Gyles C, Johnson R, Gao A, et al. Association of Enterohemorrhagic *Escherichia coli* Hemolysin with serotypes of shiga-like-toxin-producing *Escherichia coli* of human and Bovine origins. Appl Environ Microbiol. 1998 Nov 1;64(11): 4134–41.
72. Smith AM, Tau NP, Sooka A, et al. Surveillance for enterohaemorrhagic *Escherichia coli* associated with human diarrhoea in South Africa, 2006–2009. J Med Microbiol. 2011;60(5):681–3. <https://doi.org/10.1099/jmm.0.022947-0>
73. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930–6. <https://doi.org/10.1056/NEJM200006293422601>
74. Silvestro L, Caputo M, Blancato S, et al. Asymptomatic carriage of verocytotoxin-producing *Escherichia coli* O157 in farm workers in Northern Italy. Epidemiol Infect. 2004 Oct;132(5):915–9. <https://doi.org/10.1017/S0950268804002390>
75. Effler E, Isaacson M, Arntzen L, et al. Factors contributing to the emergence of *Escherichia coli* O157 in Africa. Emerging Infect Dis. 2001;7(5):812. <https://doi.org/10.3201/eid0705.017507>
76. Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for *Shigella dysenteriae* type 1 infection in Bangladesh. Clin Infect Dis. 2006;42(3): 356–62. <https://doi.org/10.1086/499236>
77. Hounsa A, Kouadio L, De Mol P. Self-medication with antibiotics obtained from private pharmacies in Abidjan, Ivory Coast]. Médecine et maladies infectieuses. 2010;40(6):333. <https://doi.org/10.1016/j.medmal.2009.10.002>
78. Vento S, Cainelli F. The need for new antibiotics. The Lancet. 2010;375(9715):637. [https://doi.org/10.1016/S0140-6736\(10\)60264-4](https://doi.org/10.1016/S0140-6736(10)60264-4)
79. EL-Alfy SM, Ahmed SF, Selim SA, et al. Prevalence and characterization of Shiga toxin O157 and non-O157 enterohemorrhagic *Escherichia coli* isolated from different sources in Ismailia, Egypt. Afr J Microbiol Res. 2013;7(21):2637–45.
80. Iweriebor BC, Iwu CJ, Obi LC, et al. Multiple antibiotic resistances among Shiga toxin producing *Escherichia coli* O157 in feces of dairy cattle farms in Eastern Cape of South Africa. BMC Microbiol. 2015;15(1):213. <https://doi.org/10.1186/s12866-015-0553-y>
81. Potter AA, Klashinsky S, Li Y, et al. Decreased shedding of *Escherichia coli* O157: H7 by cattle following vaccination with type III secreted proteins. Vaccine. 2004;22(3):362–9. <https://doi.org/10.1016/j.vaccine.2003.08.007>
82. Senhaji O, Faid M, Kalalou I. Inactivation of *Escherichia coli* O157:H7 by essential oil from *Cinnamomum zeylanicum*. Braz J Infect Dis. 2007 Apr;11(2):234–6. <https://doi.org/10.1590/S1413-86702007000200013>
83. Bielaszewska M, Idelevich EA, Zhang W, et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic *Escherichia coli* O104: H4 strain. Antimicrob Agents Chemother. 2012;56(6):3277–82. <https://doi.org/10.1128/AAC.06315-11>
84. Corogeanu D, Willmes R, Wolke M, et al. Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic *E. coli* O104: H4 from the 2011 German outbreak. BMC Microbiol. 2012;12(1):160. <https://doi.org/10.1186/1471-2180-12-160>
85. Selim SA, Ahmed SF, Aziz MHA, et al. Prevalence and characterization of Shiga-toxin O157: H7 and non-O157: H7 enterohemorrhagic *Escherichia coli* isolated from different sources. Biotechnol Biotechnol Equip. 2013;27(3):3834–42. <https://doi.org/10.5504/BBEQ.2013.0031>
86. EL-Alfy SM, Ahmed SF, Selim SA, et al. Prevalence and characterization of Shiga toxin O157 and non-O157 enterohemorrhagic *Escherichia coli* isolated from different sources in Ismailia, Egypt. Afr J Microbiol Res. 2013;7(21):2637–45.
87. Iwu CJ, Iweriebor BC, Obi LC, et al. Occurrence of non-O157 Shiga toxin-producing *Escherichia coli* in two commercial swine farms in the Eastern Cape Province, South Africa. Comp Immunol Microbiol Infect Dis. 2016;44:48–53. <https://doi.org/10.1016/j.cimid.2015.12.004>
88. Rasko DA, Webster DR, Sahl JW, et al. Origins of the *E. coli* strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med. 2011;365(8):709–17. <https://doi.org/10.1056/NEJMoa1106920>

Received: 17-09-2016 Accepted: 04-09-2017